- Home
- IDAI vs CVKD Comparison
IDAI vs CVKD Comparison
Compare IDAI & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDAI | CVKD |
|---|---|---|
| Founded | 2016 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 19.0M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | IDAI | CVKD |
|---|---|---|
| Price | $2.57 | $7.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 87.0K | 49.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.46 | N/A |
| Revenue Next Year | $99.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $4.91 |
| 52 Week High | $5.28 | $20.39 |
Technical Indicators
Market Signals| Indicator | IDAI | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 39.16 | 56.13 |
| Support Level | $1.90 | $6.64 |
| Resistance Level | $3.11 | $8.87 |
| Average True Range (ATR) | 0.28 | 0.72 |
| MACD | 0.04 | 0.16 |
| Stochastic Oscillator | 32.20 | 75.52 |
Price Performance
Historical ComparisonAbout IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.